Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission file number: 001-40880 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of the registrant as specified in its charte ...

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q1 2023 Earnings Conference Call May 9, 2023 8:30 AM ET Company Participants Allison Wey - Senior Vice President, Investor Relations, and Corporate Communications Paul Edick - Chairman and Chief Executive Officer Steve Pieper - Chief Financial Officer Conference Call Participants Oren Livnat - H.C. Wainwright Glen Santangelo - Jefferies Roanna Ruiz - SVB Securities Operator Hello all and warm welcome to the Xeris Biopharma Holding First Quarter 2023 Financial Res ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission file number: 001-40880 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of the registrant as specified in its charter) Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Delaware 87-1082097 ...

Financial Data and Key Metrics Changes - The company reported a net product revenue growth of 52% for Q4 2022 and 38% for the full year on a pro forma basis, finishing the year with $110 million in total revenue [9][34] - Cash on hand exceeded $120 million at year-end 2022, indicating strong liquidity [9] - Total net product revenue for 2022 was over $109 million, achieving the top end of guidance [34] Business Line Data and Key Metrics Changes - Gvoke achieved net revenue of $15 million in Q4 2022, a 36% increase year-over-year, with total prescriptions growing over 42% [11][12] - Keveyis generated approximately $14 million in Q4 2022, representing a 33% increase, and over $49 million for the full year, a 23% increase [17][39] - Recorlev net revenue for Q4 was $3.8 million, a 51% increase from the previous quarter, with total revenue for 2022 at $7.4 million [19][41] Market Data and Key Metrics Changes - The total glucagon market grew 6% in Q4 2022 and 9% for the full year, with Gvoke outpacing market growth [13] - Gvoke's market share of new prescriptions reached approximately 28%, with ready-to-use glucagon products representing nearly 75% of the new prescription market [14] Company Strategy and Development Direction - The company aims to achieve cash flow breakeven in Q4 2023 without needing additional capital, positioning itself as a self-sustaining enterprise [10][52] - The focus is on advancing the levothyroxine program and developing partnerships, such as the collaboration with Horizon Therapeutics for TEPEZZA [21][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued growth and the potential for a pivotal year in 2023, driven by strong revenue growth and disciplined expense management [31][55] - The company anticipates total revenues between $135 million and $165 million for 2023, reflecting a growth rate of approximately 36% from 2022 [31][42] Other Important Information - The company has not yet experienced a negative impact from the first generic entry of Keveyis, although it remains a concern for the future [17][40] - The company is preparing for potential impacts from deductible resets on patient access to Recorlev, which is common in rare disease products [72] Q&A Session Summary Question: Guidance range and factors affecting it - Management acknowledged the wider guidance range due to multiple moving parts, including the early stage of Recorlev's launch and uncertainty regarding Keveyis' generic impact [56][57] Question: Current market status of Keveyis - Management confirmed that no generics are currently operational in the market, and patient support systems are in place to maintain business [59][60] Question: Titration process for Recorlev - Management indicated that titration is slower in real-world settings compared to clinical studies, with physicians managing doses carefully [64][66] Question: Contribution from other revenues - Management noted that the contribution from partnerships and collaborations is uncertain and depends on the speed of achieving target product profiles [69][70] Question: Payer coverage for Recorlev - Management reported that prior authorization hurdles exist but success rates are better than 50%, with many appeals resulting in approvals [74][76] Question: Gvoke's growth outlook - Management expects Gvoke to continue its growth trajectory, with minimal impact from generics and a rebound in market growth [80][81] Question: Competitive dynamics for Recorlev - Management believes Recorlev is performing well against competitors, with a focus on demonstrating its efficacy compared to existing treatments [82][84] Question: Timeline for levothyroxine injectable product - Management indicated that the earliest filing for the levothyroxine injectable product could be between 2026 and 2028, depending on the Phase 2 study outcomes [87]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission file number: 001-40880 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of the registrant as specified in its charter) (State or o ...

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q3 2022 Earnings Conference Call November 9, 2022 8:30 AM ET Company Participants Allison Wey - Senior Vice President, Investor Relations and Corporate Communications Paul Edick - Chairman and CEO Steve Pieper - Chief Financial Officer Conference Call Participants Glen Santangelo - Jefferies David Amsellem - Piper Sandler Oren Livnat - H.C. Wainwright Roanna Ruiz - SVB Securities Operator Good evening or good afternoon. And welcome to the Xeris Biopharma Third Qu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission file number: 001-40880 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of the registrant as specified in its charter) (State or other ...

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q2 2022 Earnings Conference Call August 10, 2022 8:30 AM ET Company Participants Allison Wey - Senior Vice President of Investor Relations and Corporate Communications Paul Edick - Chairman and Chief Executive Officer Steve Pieper - Chief Financial Officer Conference Call Participants Roanna Ruiz - SVB Securities Oren Livnat - H.C. Wainwright David Amsellem - Piper Sandler Operator Hello, and welcome to today’s Xeris Biopharma’s Second Quarter 2022 Financial Resu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission file number: 001-40880 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of the registrant as specified in its charter) (State or other ...

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q1 2022 Earnings Conference Call May 11, 2022 8:30 AM ET Company Participants Allison Wey - SVP, IR & Corporate Communications Paul Edick - Chairman & CEO Steve Pieper - CFO Conference Call Participants David Amsellem - Piper Sandler Roanna Ruiz - SVB Securities Vamil Divan - Mizuho Securities Robin Garner - Craig-Hallum Oren Livnat - H.C. Wainwright Operator Hello, and welcome to today’s Xeris Biopharma’s First Quarter 2022 Financial Results Conference Call and ...